Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.42 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.42 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.42 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16748421 | 0.92 | AGPAT2 (0.41) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16748428 | 0.92 | AGPAT2 (0.40) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16740864 | 0.90 | BMI1 (0.48) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16748597 | 0.90 | MAPT (0.44) | RAB9ANPC1JAK2MAPTALDH1A1 | |
| SCHEMBL16748591 | 0.89 | CYBB (0.44) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16748425 | 0.88 | MAPK1 (0.36) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16740783 | 0.88 | BMI1 (0.50) | RAB9ANPC1JAK2MAPTHTT | |
| SCHEMBL16748433 | 0.87 | MAPT (0.46) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16748617 | 0.84 | BMI1 (0.52) | CYBBNOX5NOX3NOX4NOX1 | |
| SCHEMBL16740802 | 0.84 | BMI1 (0.40) | CYBBNOX5NOX3NOX4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | claimed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | claimed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | CYBB 4251/4885NOX5 3227/4885NOX3 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.